相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Immunotherapy for small cell lung cancer: mechanisms of resistance
Gerhard Hamilton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
Stefan Zimmerman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
The role of immunotherapy in small cell lung cancer
A. Calles et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Immunotherapy in extensive small cell lung cancer
Vaibhav Verma et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
Maryann R. Cooper et al.
AMERICAN JOURNAL OF THERAPEUTICS (2018)
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
David Paul Carbone et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC
C. Rudin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
L. Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Bonnie Glisson et al.
CLINICAL LUNG CANCER (2017)
SCLC-State of the Art and What Does the Future Have in Store?
Kathrin Kahnert et al.
CLINICAL LUNG CANCER (2016)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC)
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Frueh et al.
ANNALS OF ONCOLOGY (2013)
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
Konstantinos Zarogoulidis et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
The molecular pathogenesis of small cell lung cancer
Sandra P. D'Angelo et al.
CANCER BIOLOGY & THERAPY (2010)
分享论文
